ES2684517T3 - Compuestos de heterociclilo como inhibidores de MEK - Google Patents

Compuestos de heterociclilo como inhibidores de MEK Download PDF

Info

Publication number
ES2684517T3
ES2684517T3 ES13712929T ES13712929T ES2684517T3 ES 2684517 T3 ES2684517 T3 ES 2684517T3 ES 13712929 T ES13712929 T ES 13712929T ES 13712929 T ES13712929 T ES 13712929T ES 2684517 T3 ES2684517 T3 ES 2684517T3
Authority
ES
Spain
Prior art keywords
alkyl
substituted
group
unsubstituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13712929T
Other languages
English (en)
Spanish (es)
Inventor
Bhavesh Dave
Rakesh Kumar Banerjee
Samiron Phukan
Abhijit Datta Khoje
Rajkumar HANGARGE
Jitendra Sambhaji Jadhav
Venkata P. Palle
Rajender Kumar Kamboj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2684517(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Application granted granted Critical
Publication of ES2684517T3 publication Critical patent/ES2684517T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
ES13712929T 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de MEK Active ES2684517T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN288KO2012 2012-03-14
PCT/IB2013/051908 WO2013136249A1 (en) 2012-03-14 2013-03-11 Heterocyclyl compounds as mek inhibitors

Publications (1)

Publication Number Publication Date
ES2684517T3 true ES2684517T3 (es) 2018-10-03

Family

ID=47997632

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13711973T Active ES2741896T3 (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo
ES13712929T Active ES2684517T3 (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo como inhibidores de MEK

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES13711973T Active ES2741896T3 (es) 2012-03-14 2013-03-11 Compuestos de heterociclilo

Country Status (35)

Country Link
US (5) US9428499B2 (OSRAM)
EP (2) EP2834237B1 (OSRAM)
JP (3) JP6431770B2 (OSRAM)
KR (4) KR20140138910A (OSRAM)
CN (4) CN104203947A (OSRAM)
AP (2) AP3859A (OSRAM)
AU (4) AU2013234014B2 (OSRAM)
BR (1) BR112014022713B1 (OSRAM)
CA (2) CA2865167C (OSRAM)
CL (2) CL2014002411A1 (OSRAM)
CO (2) CO7160029A2 (OSRAM)
CR (2) CR20140463A (OSRAM)
CU (2) CU24272B1 (OSRAM)
DK (2) DK2834236T3 (OSRAM)
DO (2) DOP2014000203A (OSRAM)
EA (2) EA028232B1 (OSRAM)
ES (2) ES2741896T3 (OSRAM)
GE (2) GEP201706671B (OSRAM)
GT (2) GT201400195A (OSRAM)
IL (2) IL234560A (OSRAM)
IN (2) IN2014MN01755A (OSRAM)
MA (2) MA37400B1 (OSRAM)
MX (3) MX355526B (OSRAM)
MY (2) MY175950A (OSRAM)
NI (2) NI201400108A (OSRAM)
NZ (2) NZ629442A (OSRAM)
PE (2) PE20141973A1 (OSRAM)
PH (2) PH12014502041B1 (OSRAM)
PL (1) PL2834237T3 (OSRAM)
SG (2) SG11201405006PA (OSRAM)
TN (2) TN2014000356A1 (OSRAM)
TR (1) TR201811976T4 (OSRAM)
UA (2) UA114907C2 (OSRAM)
WO (2) WO2013136254A1 (OSRAM)
ZA (1) ZA201406186B (OSRAM)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PL2834237T3 (pl) 2012-03-14 2018-11-30 Lupin Limited Związki heterocyklilowe jako inhibitory mek
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
KR102222569B1 (ko) 2013-10-25 2021-03-05 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 피리딘의 케톤 유도체의 제조 방법 및 제약 용도
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
WO2016035008A1 (en) * 2014-09-04 2016-03-10 Lupin Limited Pyridopyrimidine derivatives as mek inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10898487B2 (en) 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MX2020006438A (es) * 2017-12-21 2020-09-17 Boehringer Ingelheim Int Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1.
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114375202A (zh) 2019-06-19 2022-04-19 勃林格殷格翰国际有限公司 抗癌组合疗法
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220106106A (ko) * 2019-07-30 2022-07-28 에드빈세 아베 뇌졸중 치료용 mek 억제제
EP3797899A1 (de) 2019-09-27 2021-03-31 Primetals Technologies Austria GmbH Vorrichtung und verfahren zum erkennen von einer bewegung eines körpers in einer industrieanlage
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2021285032A1 (en) 2020-06-02 2022-12-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh) * 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
JP2024514127A (ja) 2021-04-09 2024-03-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん剤療法
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
EP4323066A1 (en) * 2021-04-16 2024-02-21 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2024006681A (es) 2021-12-01 2024-08-26 Boehringer Ingelheim Int Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cancer.
CN118591540A (zh) 2021-12-01 2024-09-03 勃林格殷格翰国际有限公司 包含环状2-氨基-3-氰基噻吩的kras降解化合物
EP4441054A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN118613485A (zh) 2021-12-01 2024-09-06 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN114605408B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573581B (zh) * 2022-03-30 2023-09-01 沈阳药科大学 5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114573582B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用
CN114456166B (zh) * 2022-03-30 2023-06-16 沈阳药科大学 5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
IL316768A (en) 2022-05-25 2025-01-01 Ikena Oncology Inc MEK inhibitors and their uses
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) * 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2004293436B2 (en) 2003-11-19 2010-12-09 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
MXPA06014478A (es) * 2004-06-11 2007-03-21 Japan Tobacco Inc Derivados de 5-amino-2, 4, 7-trioxo-3, 4, 7, 8-tetrahidro -2h-pirido[2, 3-d]pirimidina y compuestos relacionados para el tratamiento del cancer.
AU2009344690A1 (en) 2009-04-21 2011-10-27 Novartis Ag Heterocyclic compounds as MEK inhibitors
PL2834237T3 (pl) * 2012-03-14 2018-11-30 Lupin Limited Związki heterocyklilowe jako inhibitory mek

Also Published As

Publication number Publication date
EP2834237B1 (en) 2018-06-06
US20150133424A1 (en) 2015-05-14
AU2017200493B2 (en) 2018-03-29
JP6630771B2 (ja) 2020-01-15
EA201491671A1 (ru) 2014-12-30
CU20140110A7 (es) 2014-11-27
IN2014MN01754A (OSRAM) 2015-07-03
KR20140138911A (ko) 2014-12-04
PE20141974A1 (es) 2014-12-12
AU2018202568B2 (en) 2019-05-09
PH12014502040A1 (en) 2014-11-24
CR20140464A (es) 2014-11-28
US9428499B2 (en) 2016-08-30
CN108383836A (zh) 2018-08-10
WO2013136249A1 (en) 2013-09-19
GEP201706671B (en) 2017-05-25
ZA201406186B (en) 2016-06-29
UA114906C2 (uk) 2017-08-28
NI201400108A (es) 2014-11-28
CL2014002412A1 (es) 2015-03-06
DOP2014000203A (es) 2015-02-15
DOP2014000204A (es) 2015-02-15
JP6431770B2 (ja) 2018-11-28
US20150299186A1 (en) 2015-10-22
PH12014502040B1 (en) 2014-11-24
IL234560A (en) 2017-06-29
EA028232B1 (ru) 2017-10-31
HK1202538A1 (en) 2015-10-02
CN104203947A (zh) 2014-12-10
CO7170131A2 (es) 2015-01-28
AU2017200493A1 (en) 2017-02-16
JP2018115215A (ja) 2018-07-26
US20170112840A1 (en) 2017-04-27
CA2865164C (en) 2021-06-08
AP3834A (en) 2016-09-30
EP2834236A1 (en) 2015-02-11
BR112014022713A2 (OSRAM) 2017-06-20
PH12014502041A1 (en) 2014-11-24
NZ629442A (en) 2016-12-23
AP2014008008A0 (en) 2014-10-31
TR201811976T4 (tr) 2018-09-21
AU2013234014A1 (en) 2014-09-25
EA029768B1 (ru) 2018-05-31
DK2834237T3 (en) 2018-08-27
CU20140109A7 (es) 2014-11-27
CN108383836B (zh) 2021-11-12
MX355474B (es) 2018-04-16
US20170101408A1 (en) 2017-04-13
AP3859A (en) 2016-10-31
JP6093384B2 (ja) 2017-03-08
MX366426B (es) 2019-07-08
US9969731B2 (en) 2018-05-15
US20160331753A1 (en) 2016-11-17
MA37400B1 (fr) 2019-11-29
AP2014008009A0 (en) 2014-10-31
AU2013234009B2 (en) 2016-10-27
CL2014002411A1 (es) 2015-04-06
KR20190073597A (ko) 2019-06-26
GT201400196A (es) 2017-09-28
DK2834236T3 (da) 2019-08-26
CU24335B1 (es) 2018-04-03
PH12014502041B1 (en) 2014-11-24
CA2865167A1 (en) 2013-09-19
KR102240101B1 (ko) 2021-04-14
WO2013136254A1 (en) 2013-09-19
IN2014MN01755A (OSRAM) 2015-07-03
JP2015509975A (ja) 2015-04-02
AU2013234009A1 (en) 2014-09-25
AU2018202568A1 (en) 2018-05-10
PL2834237T3 (pl) 2018-11-30
MA37405A1 (fr) 2016-03-31
MX2014010928A (es) 2015-04-10
MX2014010925A (es) 2015-04-10
EP2834237A1 (en) 2015-02-11
CU24272B1 (es) 2017-08-08
MA37400A1 (fr) 2016-05-31
CA2865164A1 (en) 2013-09-19
TN2014000357A1 (en) 2015-12-21
UA114907C2 (uk) 2017-08-28
EP2834236B1 (en) 2019-05-22
MY175950A (en) 2020-07-16
TN2014000356A1 (en) 2015-12-21
KR20190100472A (ko) 2019-08-28
SG11201405007QA (en) 2014-10-30
US9573944B2 (en) 2017-02-21
CN104271577A (zh) 2015-01-07
NZ629432A (en) 2017-01-27
US9555035B2 (en) 2017-01-31
HK1206020A1 (en) 2015-12-31
JP2015514056A (ja) 2015-05-18
PE20141973A1 (es) 2014-12-12
ES2741896T3 (es) 2020-02-12
GEP201706774B (en) 2017-11-27
MX355526B (es) 2018-04-20
NI201400107A (es) 2014-11-26
BR112014022713B1 (pt) 2021-09-08
SG11201405006PA (en) 2014-10-30
KR20140138910A (ko) 2014-12-04
AU2013234014B2 (en) 2017-02-02
MY174188A (en) 2020-03-12
CO7160029A2 (es) 2015-01-15
EA201491672A1 (ru) 2014-12-30
CA2865167C (en) 2019-08-06
GT201400195A (es) 2017-11-09
CN107698585A (zh) 2018-02-16
CR20140463A (es) 2014-11-28
KR102241111B1 (ko) 2021-04-15
US9827247B2 (en) 2017-11-28
IL234559A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
ES2684517T3 (es) Compuestos de heterociclilo como inhibidores de MEK
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
AR109788A1 (es) Compuestos de benzo[b]tiofeno como agonistas de sting
PE20181024A1 (es) Derivados de ciclohexano sustituido con amido
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
AR103138A1 (es) Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MX2016012984A (es) Derivados indol para uso en medicina.
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR094300A1 (es) Derivados de quinolonas
ES2626801T3 (es) Compuestos de triazolopiridina como inhibidores de pde10a
AR105893A1 (es) Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato
MX2016012451A (es) Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina.
AR104262A1 (es) Derivados de cromeno como inhibidores de las fosfoinositido-3 quinasas
PH12015502851A1 (en) Curable composition
AR102825A1 (es) Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre
AR091534A1 (es) Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco
AR115020A1 (es) Compuesto heterocíclico nitrogenado y su uso como antagonista del receptor nmda
AR106958A1 (es) Derivados de tetrahidrotriazolopirimidina útiles como inhibidores de hne